| MORPHOSYS AG | 87.32 / +0.39% |
| Date/Time | 10/30 / 17:32 |
| Chg. / Chg.(%) | 0.34 / +0.39% |
| Bid | - |
| Ask | - |
| Open | 85.60 |
| Previous Close | 86.98 |
| High | 87.32 |
| Low | 85.60 |
| Volume [EUR] | 174.32 |
| Volume [Units] | 2 |
| Price fixings | 3 |
| ISIN | DE0006632003 |
| Security | MOR |
| Exchange | Vienna Global Market |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Xetra | 87.56 |  |
159,049 |
| Cboe Europe .. | 87.30 | |
31,247 |
| London Inter.. | 87.30 | |
14,433 |
| TradeGate | 87.600 | |
8,634 |
| Turquoise | 87.32 | |
7,637 |
| Cboe Europe .. | 87.56 | |
6,286 |
| Frankfurt | 87.2400 | |
379 |
| Stuttgart | 87.100 | |
281 |
| gettex | 87.040 | |
111 |
| Hamburg | 86.54 |  |
50 |
| Vienna Globa.. | 87.32 | |
2 |
| Hannover | 85.82 | |
0 |
| Berlin | 85.80 | |
0 |
| München | 85.84 | |
0 |
| Düsseldorf | 85.74 |  |
0 |
| Lang & Schwa.. | 86.820 | |
|
| SIX Swiss Ex.. | 102.00 | ||
| Nasdaq Other.. | 98.3000 | 1,403 | |
| EUREX | Options | ||
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
01/31/2019 / 13:36 - GlobeNewswire
Real-time